News|Articles|October 26, 2023
Inside Look at Resilience’s Latest Viral Vector Manufacturing Site
Author(s)Resilience
Designed for advanced therapy manufacturing, the Marlborough, MA facility is the first new construction at Resilience. The site will produce, rest, and release viral vector drug substance (DS) and drug product (DP), for clinical and commercial use.
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Related Content
Trending on BioPharm International
1
Developing Next-Gen Cell Lines Using Targeted Integration
2
FAQ: What You Need to Know about the Current Antibody Pipeline
3
FDA-Approved WAS Gene Therapy Hits Market in Nonprofit Model
4
EU Clears Subcutaneous Biologic for Lupus, Advancing Patient-Controlled Delivery
5